M Becx-Bleumink

507 total citations
25 papers, 365 citations indexed

About

M Becx-Bleumink is a scholar working on Infectious Diseases, Epidemiology and Genetics. According to data from OpenAlex, M Becx-Bleumink has authored 25 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 7 papers in Epidemiology and 5 papers in Genetics. Recurrent topics in M Becx-Bleumink's work include Leprosy Research and Treatment (14 papers), Tuberculosis Research and Epidemiology (12 papers) and Mycobacterium research and diagnosis (6 papers). M Becx-Bleumink is often cited by papers focused on Leprosy Research and Treatment (14 papers), Tuberculosis Research and Epidemiology (12 papers) and Mycobacterium research and diagnosis (6 papers). M Becx-Bleumink collaborates with scholars based in Ethiopia, United States and Netherlands. M Becx-Bleumink's co-authors include Derbew Fikadu Berhe, Rolf Kiessling, Gerald E. Hancock, Gilla Kaplan, Matthew J. Dietz, Tom H. M. Ottenhoff, Paul J. Converse, C. K. Job, Zanvil A. Cohn and Anthony G. Molloy and has published in prestigious journals such as The Journal of Experimental Medicine, The Journal of Infectious Diseases and Cellular Immunology.

In The Last Decade

M Becx-Bleumink

23 papers receiving 328 citations

Peers

M Becx-Bleumink
Elizabeth Race United States
Barbara M. Stryjewska United States
D. L. LEIKER Netherlands
S Žerjav Serbia
Cari Stek United Kingdom
Elizabeth Race United States
M Becx-Bleumink
Citations per year, relative to M Becx-Bleumink M Becx-Bleumink (= 1×) peers Elizabeth Race

Countries citing papers authored by M Becx-Bleumink

Since Specialization
Citations

This map shows the geographic impact of M Becx-Bleumink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Becx-Bleumink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Becx-Bleumink more than expected).

Fields of papers citing papers by M Becx-Bleumink

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Becx-Bleumink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Becx-Bleumink. The network helps show where M Becx-Bleumink may publish in the future.

Co-authorship network of co-authors of M Becx-Bleumink

This figure shows the co-authorship network connecting the top 25 collaborators of M Becx-Bleumink. A scholar is included among the top collaborators of M Becx-Bleumink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Becx-Bleumink. M Becx-Bleumink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Werf, Marieke J. van der, et al.. (2007). Viewpoint: do we have enough data to estimate the current burden of tuberculosis? The example of Bangladesh. Tropical Medicine & International Health. 12(3). 317–322. 2 indexed citations
2.
Becx-Bleumink, M, Christopher Gilpin, Moses Joloba, et al.. (2007). Ziehl-Neelsen staining: strong red on weak blue, or weak red under strong blue?. PubMed. 11(11). 1160–1. 8 indexed citations
4.
Becx-Bleumink, M, et al.. (2001). High tuberculosis notification and treatment success rates through community participation in central Sulawesi, Republic of Indonesia.. PubMed. 5(10). 920–5. 16 indexed citations
5.
Becx-Bleumink, M, et al.. (2001). Short-course instead of long-course chemotherapy for smear-negative patients in sub-Saharan Africa.. PubMed. 5(1). 4–11. 2 indexed citations
6.
Becx-Bleumink, M, et al.. (1996). Eliminating leprosy as a public health problem--is the optimism justified?. PubMed. 17(2). 109–44. 14 indexed citations
7.
Becx-Bleumink, M. (1994). Multidrug therapy in the control of leprosy. A field study.. PubMed. 46(2). 109–14. 4 indexed citations
8.
Becx-Bleumink, M & Derbew Fikadu Berhe. (1992). Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.. PubMed. 60(2). 173–84. 80 indexed citations
9.
Becx-Bleumink, M. (1992). Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.. PubMed. 60(3). 421–35. 20 indexed citations
10.
Becx-Bleumink, M. (1992). Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the all Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.. PubMed. 60(2). 161–72. 6 indexed citations
11.
Becx-Bleumink, M. (1992). Duration of multidrug therapy in paucibacillary leprosy patients; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.. PubMed. 60(3). 436–44. 4 indexed citations
12.
Becx-Bleumink, M, et al.. (1991). Urinary Phenolic Glycolipid 1 in the Diagnosis and Management of Leprosy. The Journal of Infectious Diseases. 163(3). 653–656. 7 indexed citations
13.
Becx-Bleumink, M. (1991). Allocation of patients to paucibacillary or multibacillary drug regimens for the treatment of leprosy--a comparison of methods based mainly on skin smears as opposed to clinical methods--alternative clinical methods for classification of patients.. PubMed. 59(2). 292–303. 12 indexed citations
14.
Becx-Bleumink, M. (1991). Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients.. PubMed. 59(4). 558–68. 2 indexed citations
15.
Hancock, Gerald E., Anthony G. Molloy, Abhijit Kale, et al.. (1991). In vivo administration of low-dose human interleukin-2 induces lymphokine-activated killer cells for enhanced cytolysis in vitro. Cellular Immunology. 132(2). 277–284. 12 indexed citations
16.
Converse, Paul J., Tom H. M. Ottenhoff, Gerald E. Hancock, et al.. (1990). Intradermal Recombinant Interleukin 2 Enhances Peripheral Blood T‐Cell Responses to Mitogen and Antigens in Patients with Lepromatous Leprosy. Scandinavian Journal of Immunology. 32(2). 83–91. 17 indexed citations
17.
Becx-Bleumink, M, et al.. (1990). THE MANAGEMENT OF NERVE DAMAGE IN THE LEPROSY CONTROL SERVICES. Leprosy Review. 61(1). 1–11. 33 indexed citations
18.
Kaplan, Gilla, Rolf Kiessling, Gerald E. Hancock, et al.. (1989). The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2.. The Journal of Experimental Medicine. 169(3). 893–907. 84 indexed citations
19.
Becx-Bleumink, M. (1986). Operational aspects of the implementation of multidrug therapy at ALERT, Ethiopia.. Leprosy Review. 57. 115–23.
20.
Becx-Bleumink, M. (1984). NEW DEVELOPMENTS IN ALERT LEPROSY CONTROL PROGRAMME AND THE ISSUES OF INTEGRATION. Ethiopian Journal of Health Development. 1(2). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026